Advertisement
U.S. markets open in 2 hours 20 minutes
  • S&P Futures

    5,201.75
    -13.00 (-0.25%)
     
  • Dow Futures

    39,159.00
    -64.00 (-0.16%)
     
  • Nasdaq Futures

    18,174.75
    -56.75 (-0.31%)
     
  • Russell 2000 Futures

    2,044.10
    -5.70 (-0.28%)
     
  • Crude Oil

    82.55
    -0.17 (-0.21%)
     
  • Gold

    2,157.60
    -6.70 (-0.31%)
     
  • Silver

    25.14
    -0.13 (-0.51%)
     
  • EUR/USD

    1.0850
    -0.0027 (-0.25%)
     
  • 10-Yr Bond

    4.3400
    0.0000 (0.00%)
     
  • Vix

    14.61
    +0.28 (+1.95%)
     
  • GBP/USD

    1.2685
    -0.0043 (-0.34%)
     
  • USD/JPY

    150.5260
    +1.4280 (+0.96%)
     
  • Bitcoin USD

    62,923.91
    -5,090.79 (-7.48%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,706.67
    -15.88 (-0.21%)
     
  • Nikkei 225

    40,003.60
    +263.20 (+0.66%)
     

Pharmaceutical ETFs Break Out on Horizon Pharma’s Positive Drug Results

This article was originally published on ETFTrends.com.

Pharmaceutical sector-related ETFs stood out Thursday after Horizon Pharma (HZNP) revealed positive test results for its treatment of thyroid eye disease, or TED.

Among the better performing non-leveraged ETFs of Thursday, the First Trust Nasdaq Pharmaceuticals ETF (FTXH) rose 1.8%, Invesco Dynamic Pharmaceuticals ETF (PJP) gained 1.5% and SPDR Pharmaceuticals ETF (XPH) increased 2.3%. Both FTXH and PJP were also testing their long-term resistance at the 200-day simple moving average.

Horizon Pharma shares surged 32.5% Thursday following the release of positive test results in its Phase 3 trial of its thyroid eye disease drug, teprotumumab, TheStreet reports.

HZNP makes up 4.0% of FTXH's underlying holdings, 3.0% of PJP's holdings and 2.6% of XPH.

According to the pharmaceutical company's reports, merely 83% of TED patients given teprotumumab had a "meaningful improvement in in proptosis, or bulging of the eye," the main cause of morbidity in the disease.

Horizon announced it will submit an application for a biologics license mid-year to the U.S. Food and Drug Administration for its proposed treatment of the thyroid eye disease. The company will also revealed detailed data later this year to a peer-reviewed journal and to a medical conference.

If the FDA approves teprotumumab, Horizon's new drug would be the first on the market to treat TED, a rare eye disease that afflicts as many as 20,000 people each year in the U.S.

A "progressive, debilitating autoimmune disease," TED can cause eye bulging, misalignment of the eyes, double vision and, in some cases, blindness, according to Horizon.

"The dramatic results of the teprotumumab Phase 3 confirmatory trial ... form a highly convincing body of clinical evidence supporting teprotumumab for the treatment of active thyroid eye disease," Timothy Walbert, chairman, president and CEO of Horizon, said in a note. "This is a key milestone as we evolve into a research-focused company."

For more information on the market sectors, visit our sector ETFs category.

POPULAR ARTICLES AND RESOURCES FROM ETFTRENDS.COM

READ MORE AT ETFTRENDS.COM >

Advertisement